Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1795091 combination immunotherapy study in advanced solid tumors
NL-OMON46814Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of GSK1795091, gsk3174998, feladilimab and pembrolizumab in Nonhematologic neoplasms and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by GSK. Primary endpoints: Adverse events, Serious adverse events and 4 more. Started Sep 2018; status: active, not recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON46814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46814.